0QIU Stock Overview
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 721.01 |
| 52 Week High | DKK 1,032.20 |
| 52 Week Low | DKK 645.70 |
| Beta | 0.16 |
| 11 Month Change | -11.34% |
| 3 Month Change | -21.16% |
| 1 Year Change | 2.55% |
| 33 Year Change | 94.26% |
| 5 Year Change | 279.13% |
| Change since IPO | 170.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QIU | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -5.8% | -1.0% | -0.4% |
| 1Y | 2.5% | -4.0% | 5.6% |
Return vs Industry: 0QIU exceeded the UK Pharmaceuticals industry which returned -4% over the past year.
Return vs Market: 0QIU underperformed the UK Market which returned 5.6% over the past year.
Price Volatility
| 0QIU volatility | |
|---|---|
| 0QIU Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0QIU has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0QIU's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 71,880 | Lars Jorgensen | www.novonordisk.com |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S Fundamentals Summary
| 0QIU fundamental statistics | |
|---|---|
| Market cap | DKK 3.15t |
| Earnings (TTM) | DKK 94.72b |
| Revenue (TTM) | DKK 270.58b |
33.3x
P/E Ratio11.6x
P/S RatioIs 0QIU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QIU income statement (TTM) | |
|---|---|
| Revenue | DKK 270.58b |
| Cost of Revenue | DKK 41.51b |
| Gross Profit | DKK 229.07b |
| Other Expenses | DKK 134.35b |
| Earnings | DKK 94.72b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
| Earnings per share (EPS) | 21.38 |
| Gross Margin | 84.66% |
| Net Profit Margin | 35.01% |
| Debt/Equity Ratio | 47.3% |
How did 0QIU perform over the long term?
See historical performance and comparison